
Opinion|Videos|August 1, 2024
IPF and PDE4B Inhibitors
Author(s)Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
- How do PDE4 inhibitors differ from PDE4B inhibitors?
- Why is this pathway of interest to pulmonologists and patients living with IPF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
WHO Publishes GLP-1 Guidelines for Obesity Treatment
2
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
3
Frameworks for Advancing Health Equity: Dental Health Care Access
4
Shaping the Future of Community Oncology Through Sustainable Practices
5















































